Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis
Abstract
Objective: HER2/Neu is a growth-factor receptor expressed in 30% of uterine serous carcinomas (USC). Based on the preliminary results of a multicenter, randomized phase II trial, trastuzumab (a humanized monoclonal antibody targeting HER2/Neu) in combination with carboplatin/paclitaxel is now recognized as an alternative standard in treating advanced or recurrent HER2/Neu+ USC. Herein, we report updated survival...
Paper Details
Title
Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis
Published Date
Oct 1, 2020
Journal
Volume
159
Pages
7 - 8
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History